国产99久久精品_欧美日本韩国一区二区_激情小说综合网_欧美一级二级视频_午夜av电影_日本久久精品视频

美國PhaseBio  
作為一家開發治療糖尿病、代謝性疾病和心血管疾病等藥物臨床階段的生物技術私人企業——PhaseBio藥物有限公司

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs with an initial focus on endocrine, metabolic and cardiovascular disease. The company uses a proprietary class of recombinant biopolymers called elastin-like polymers (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides that have been shown to be clinically active with the goal of achieving greater drug potency, fewer side effects and better patient compliance.

The ELP technology was first developed by Ashutosh Chilkoti, Ph.D., Professor of Biomedical Engineering at Duke University and further enhanced by PhaseBio scientists to create long acting biopharmaceuticals. PhaseBio has two lead programs. Our first lead candidate Glymera, is currently being evaluated in humans for the treatment of hyperglycemia associated with Type 2 diabetes with potential for future use in obesity. Our second candidate Vasomera?, with an expected IND filing in 2011 will be tested as a treatment for resistant hypertension with potential for future use in Pulmonary Arterial Hypertension (PAH) and heart failure. PhaseBio has headquarters and research laboratories in Malvern, Pennsylvania.